Impact
Using these plans the company initiated & completed
Ph2a trials in all 3 indications
Data from these trials supported a successful funding round
Company has initiated a Ph2b trial also designed with
Weatherden support
INDICATION PRIORITIZATION - CLINICAL TRIAL DESIGN
04
Weatherden designed full Ph2a clinical development plan for top 3 indications, spanning protocol synopses, site identification and clinical/scientific
oversight for the client
03
Particular focus on identifying
key quantitative endpoints
to robustly demonstrate
proof-of-mechanism and provide preliminary
clinical proof-of-concept
02
Conducted a structured prioritization of indications, balancing scientific rationale, clinical trial feasibility, commercial opportunity,
and development risk
01
Developed a translational medicine plan to confirm target engagement and proof-of-mechanism for the
asset using next-generation, multi-modality imaging
Challenge
Company held asset with a novel MoA with potential applications in multiple indications. Weatherden was challenged to develop early clinical development plans to demonstrate the asset’s pipeline-in-a-pill potential